Triasima Portfolio Management inc. Acquires 127 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Triasima Portfolio Management inc. increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,660 shares of the pharmaceutical company’s stock after purchasing an additional 127 shares during the quarter. Triasima Portfolio Management inc.’s holdings in Vertex Pharmaceuticals were worth $4,695,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Northwest Investment Counselors LLC bought a new stake in shares of Vertex Pharmaceuticals in the third quarter worth $25,000. Highline Wealth Partners LLC bought a new stake in shares of Vertex Pharmaceuticals in the third quarter worth $27,000. Dunhill Financial LLC grew its stake in shares of Vertex Pharmaceuticals by 70.6% in the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 24 shares during the last quarter. Brown Lisle Cummings Inc. acquired a new position in Vertex Pharmaceuticals in the fourth quarter valued at $30,000. Finally, Legacy Investment Solutions LLC bought a new stake in Vertex Pharmaceuticals during the third quarter valued at $33,000. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Down 1.5 %

NASDAQ:VRTX opened at $481.16 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The firm has a market cap of $123.91 billion, a price-to-earnings ratio of -241.79, a price-to-earnings-growth ratio of 2.39 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The firm has a 50-day moving average price of $435.84 and a two-hundred day moving average price of $462.87.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter last year, the business posted $3.67 EPS. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRTX has been the topic of a number of research analyst reports. Scotiabank upped their price target on shares of Vertex Pharmaceuticals from $430.00 to $433.00 and gave the company a “sector perform” rating in a research report on Friday, January 31st. JPMorgan Chase & Co. cut their price target on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a research report on Monday, December 23rd. Raymond James reaffirmed a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. Bank of America cut their price target on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a research report on Thursday, December 19th. Finally, Truist Financial cut their price target on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating on the stock in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $502.58.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.